BLASUBCUTANEOUSSOLUTION
Approved
Sep 2015
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
TRESIBA (insulin degludec) by Novo Nordisk. Approved for insulin analog [epc]. First approved in 2015.
Drug data last refreshed 19h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Tresiba (insulin degludec) is a long-acting basal insulin analog administered via subcutaneous injection as a solution. It is indicated for the treatment of diabetes mellitus in patients requiring insulin therapy. The drug works by mimicking endogenous insulin, binding to insulin receptors to facilitate glucose uptake and utilization. Tresiba represents a newer generation basal insulin offering improved pharmacokinetics with a longer duration of action and more stable glucose control compared to older insulin analogs.
$0.0BPart D
Mechanism of Action
Pharmacologic Class:
Insulin Analog
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Phase 2b Trial Comparing HDV-Insulin Lispro to Insulin Lispro in Adults With Type 1 Diabetes Receiving Insulin Degludec
Started Jan 2024
227 enrolled
Diabetes Mellitus, Type 1
A Research Study in Saudi Arabia to Understand How the Dose Check App Used With Tresiba Treatment Helps to Control Blood Sugar Level
Started Nov 2023
179 enrolled
Diabetes Mellitus, Type 2
A Study of Insulin Degludec/Insulin Aspart Biosimilar (22011) Compared With Insulin Degludec/Insulin Aspart(Ryzodeg) in Participants With Type 2 Diabetes in China
Started May 2023
408 enrolled
Diabetes
A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy
Started Aug 2022
692 enrolled
Type 1 DiabetesDiabetes
A Research Study Looking at Blood Sugar Control in People With Type 2 Diabetes Previously Treated With Premix Insulin and Initiating Treatment With Insulin Degludec/Liraglutide (IDegLira) in Local Clinical Practice in Croatia
Started Jul 2022
0Diabetes Mellitus, Type 2
Worked on TRESIBA at Novo Nordisk? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.